A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes identity confirmation genuinely useful here.
Take the reasoning and check the arithmetic; I do not always get it right.
Injection-site reactions are reported more often in this family than for the incretins. Whether that is the compounds or the preparations they are typically supplied in is not established.
I looked this up rather than remembered it, which is the right order.
Post #8 describes the usual case. This is about the unusual one.
A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes identity confirmation genuinely useful here.
The evidence for this is thinner than the way I have phrased it suggests.
Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what most people are taking them for.
I read post #26 twice before replying, because I had assumed the opposite.
On analysis: these are short peptides and generally straightforward chromatographically, which means a poor purity result is more likely to reflect the synthesis than the method.
Published human data on most of this family is thin, old, or from small studies with surrogate endpoints. That is a genuine limitation and it is the honest answer to most questions in this subcategory.
Adding it in case it saves somebody the afternoon it cost me.
A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes identity confirmation genuinely useful here.
Read the full topic (53 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion
On the subject in the title: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Working notes rather than a conclusion. Asking about GHRH analogues versus ghrelin mimetics…
|
+47 | 53 | 6.9k | 2h |
|
Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset
The question in the title: Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset I will give what I have already checked below so nobody repeats it. Posting a small dataset…
|
+60 | 64 | 25k | 15mo |
|
IGF-1 as a surrogate endpoint and its limitations — the long version
On the subject in the title: IGF-1 as a surrogate endpoint and its limitations — the long version Working notes rather than a conclusion. A narrow question about IGF-1, deliberately narrow, because the broad…
|
+14 | 18 | 53k | 12mo |
|
Revisiting: What a well-designed human trial of a secretagogue would look like
On the subject in the title: Revisiting: What a well-designed human trial of a secretagogue would look like Working notes rather than a conclusion. Something about well-designed human trial does not reconcile…
|
+69 | 74 | 25k | 18mo |
|
CJC-1295 with and without DAC: what the modification does — what changed since
CJC-1295 with and without DAC: what the modification does — what changed since Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of…
|
4 | 5.1k | 7mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Naming conventions for research peptides and the confusion they cause
Posting this under the heading it deserves: Naming conventions for research peptides and the confusion they cause Everything below is what sits behind that. I was wrong about naming conventions for research…
|
+21 | 25 | 4.9k | 22d |
|
TB-500 and thymosin beta-4: the fragment versus the protein — does this still hold?
TB-500 and thymosin beta-4: the fragment versus the protein — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Two things I would like separated…
|
+19 | 23 | 4.2k | 19mo |
|
Oral versus injected administration claims for BPC-157
Oral versus injected administration claims for BPC-157 — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin oral versus injected administration claims…
|
+20 | 24 | 47k | 4mo |
|
Coming back to: A structured critique template this community uses
Posting this under the heading it deserves: A structured critique template this community uses Everything below is what sits behind that. Reading back through what has been written here about structured…
|
+63 | 69 | 17k | 18h |
|
Why catalogue breadth is not evidence of anything
Why catalogue breadth is not evidence of anything I have a specific reason for asking rather than idle curiosity, and the context is below. What changes if the standard account of catalogue breadth is wrong?…
|
2 | 38k | 2d |